A
Alexander Abadir
Researcher at Rockefeller University
Publications - 5
Citations - 1982
Alexander Abadir is an academic researcher from Rockefeller University. The author has contributed to research in topics: Internal medicine & Inflammatory bowel disease. The author has an hindex of 3, co-authored 3 publications receiving 1829 citations.
Papers
More filters
Journal ArticleDOI
Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding.
Johannes F. Scheid,Hugo Mouquet,Beatrix Ueberheide,Ron Diskin,Florian Klein,Thiago Y. Oliveira,John Pietzsch,John Pietzsch,David Fenyö,Alexander Abadir,Klara Velinzon,Arlene Hurley,Sunnie Myung,Farid Boulad,Pascal Poignard,Pascal Poignard,Dennis R. Burton,Dennis R. Burton,Florencia Pereyra,Florencia Pereyra,David D. Ho,Bruce D. Walker,Bruce D. Walker,Bruce D. Walker,Michael S. Seaman,Pamela J. Bjorkman,Pamela J. Bjorkman,Brian T. Chait,Michel C. Nussenzweig,Michel C. Nussenzweig +29 more
TL;DR: Anti-HIV broadly neutralizing antibodies with similar specificities and modes of binding were found in multiple HIV-infected individuals, and cloned 576 new HIV antibodies from four unrelated individuals to determine whether they are part of a larger group of related molecules.
Journal ArticleDOI
HIV therapy by a combination of broadly neutralizing antibodies in humanized mice
Florian Klein,Ariel Halper-Stromberg,Joshua A. Horwitz,Henning Gruell,Henning Gruell,Johannes F. Scheid,Johannes F. Scheid,Stylianos Bournazos,Hugo Mouquet,Linda Spatz,Linda Spatz,Ron Diskin,Alexander Abadir,Trinity Zang,Marcus Dorner,Eva Billerbeck,Rachael N. Labitt,Christian Gaebler,Christian Gaebler,Paola Marcovecchio,Reha Baris Incesu,Thomas Eisenreich,Paul D. Bieniasz,Paul D. Bieniasz,Michael S. Seaman,Pamela J. Bjorkman,Jeffrey V. Ravetch,Alexander Ploss,Michel C. Nussenzweig,Michel C. Nussenzweig +29 more
TL;DR: Combinations of potent monoclonal antibodies can effectively control HIV-1 replication in humanized mice, and should be re-examined as a therapeutic modality in HIV- 1-infected individuals.
Journal ArticleDOI
Increasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design
Ron Diskin,Johannes F. Scheid,Johannes F. Scheid,Paola Marcovecchio,Anthony P. West,Florian Klein,Han Gao,Priyanthi N. P. Gnanapragasam,Alexander Abadir,Michael S. Seaman,Michel C. Nussenzweig,Michel C. Nussenzweig,Pamela J. Bjorkman +12 more
TL;DR: Structural analysis of an HIV antibody reveals residues important for neutralization breadth and potency, which indicate that gp120 inner domain and bridging sheet residues should be included in immunogens to elicit CD4bs antibodies.
Journal ArticleDOI
680 a large multicenter study assessing factors causing delays in initiating biologic or novel small molecule therapy in patients with inflammatory bowel disease.
Alexander Abadir,Konstantinos Papamichail,Angela Troia,Hyder Said,Spurthi Tarugu,Nathan K Sairam,Scott B. Minchenberg,Anna H. Owings,Adam M. Parker,Brandon Brousse,Benjamin C. Billingsley,Alexander Carlyle,Bobby Owens,Pegah Hosseini-Carroll,Joseph Frasca,Sarah C. Glover,Adam S. Cheifetz +16 more
Journal ArticleDOI
S767 Hospitalization and Surgery Rates in Patients Awaiting Approval of Biologics or Small Molecules for Treating Inflammatory Bowel Disease (IBD)
Adam M. Parker,Brandon Brousse,Benjamin C. Billingsley,Alexander Carlyle,Alexander Abadir,Bobby Owens,Pegah Hosseini-Carroll,Konstantinos Papamichail,Adam S. Cheifetz +8 more
TL;DR: In this article , patients treated with miri in both induction and maintenance studies were more likely to achieve an FC# 250 mg/g and showed significantly greater reductions from baseline in FC and CRP when compared to PBO.